Welcome to our dedicated page for COLLEGIUM PHARMACEUTICAL SEC filings (Ticker: COLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Collegium Pharmaceutical, Inc. filings document regulatory disclosures for a commercial biopharmaceutical company with ADHD and pain-management medicines. Form 8-K reports cover operating results, earnings presentations, Regulation FD materials, guidance, material agreements, capital-structure matters and clinical or regulatory disclosures tied to the company's product portfolio.
Proxy materials describe shareholder voting matters, board composition, director nominations, board succession, executive compensation and governance practices. The filing record also captures product-related risk disclosures and formal public-company reporting for Collegium's Nasdaq-listed common stock.
Collegium Pharmaceutical reported modest top-line growth but weaker profitability for the quarter ended June 30, 2026. Net product revenues were $199,878 for the quarter and $393,398 for the first six months, up from the prior-year periods. Gross profit reached $110,292 in the quarter, but higher selling, general and administrative expense of $106,594, along with $62,953 of intangible amortization, reduced income from operations to $3,698. After net interest expense and taxes, the company posted a quarterly net loss of $15,051 and a six‑month net loss of $555, or $(0.46) per diluted share in the quarter.
The balance sheet expanded following the Azstarys acquisition, with total assets of $2,135,790, including $1,186,084 of net intangible assets and $190,177 of goodwill. Total liabilities were $1,823,881, driven by term notes payable of $797,824, convertible senior notes of $238,733, a deferred royalty obligation of $121,357 and $38,525 of contingent consideration. Total purchase consideration for Azstarys was $706,253, funded by $355,600 of cash on hand and a $300,000 delayed draw term loan. Operating cash flow was $128,436 for the six months, while investing outflows of $500,964 and financing inflows of $270,747 led to cash, cash equivalents and restricted cash of $150,377 at period end.
Collegium Pharmaceutical reported Q2 2026 results with product revenues, net of $199.9 million, up 6% year-over-year, driven by its ADHD and pain portfolios. JORNAY PM net revenue reached $46.1 million, up 41%, and newly acquired AZSTARYS contributed $12.9 million from a partial quarter.
Profitability metrics remained strong on an adjusted basis. Despite a GAAP net loss of $15.1 million, or $0.46 per share, non-GAAP adjusted net income was $75.4 million with adjusted earnings per share of $1.92. Adjusted EBITDA rose to $113.8 million, up 8%, and operating cash flow was $71.3 million, ending the quarter with $129.5 million in cash and cash equivalents.
Guidance for 2026 was updated. Product revenues, net are now expected between $825 million and $855 million and adjusted EBITDA between $445 million and $470 million, reflecting lower-than-expected authorized generic Nucynta pricing, while JORNAY PM guidance is unchanged and AZSTARYS revenue guidance increased to $65–$75 million.
Principal Global Investors filed a Schedule 13G reporting a passive ownership position in Collegium Pharmaceutical, Inc. common stock. The firm reports beneficial ownership of 1,632,360 shares of common stock, par value $0.001 per share, representing 5% of the outstanding class.
Principal Global Investors has no sole voting or dispositive power over these shares but reports shared voting and shared dispositive power over 1,632,360 shares. The filing identifies Principal Global Investors as a Delaware entity, with its principal office in Des Moines, Iowa, and Collegium Pharmaceutical’s principal executive offices in Stoughton, Massachusetts.
Vanguard Capital Management LLC filed a Schedule 13G reporting passive ownership of 1,625,821 shares of Collegium Pharmaceutical Inc. common stock, representing 5.01% of the class. Vanguard has sole voting power over 244,560 shares and sole dispositive power over all 1,625,821 shares, with no shared voting or dispositive power. The position aggregates securities beneficially owned, or deemed beneficially owned, by Vanguard Capital Management LLC and specified affiliates and business divisions, including holdings of Vanguard funds and managed accounts for which they exercise voting and/or dispositive power. No other single person has an interest in more than 5% of the securities reported.
John A. Fallon filed to sell 13,920 shares of common stock of COLL through Fidelity Brokerage Services LLC, with an aggregate market value of $497,429.27, around July 17, 2026. The shares relate to a stock option exercise. During the prior three months, Fallon sold 8,095 shares on July 15, 2026 for $294,010.40. Shares outstanding are listed as 32,433,779 as context.
Collegium Pharmaceutical, Inc. filed an amended Form 8-K to provide detailed historical and pro forma financial information related to its acquisition of AZSTARYS. Collegium completed the purchase of interests in GPC Commave Holding, LLC and Commave Sub, LLC, gaining AZSTARYS, an ADHD treatment for patients 6 and older.
The aggregate cash consideration at closing was approximately $655.6 million, funded by about $355.6 million of existing cash and $300.0 million from a delayed draw term loan under its 2025 credit agreement. Collegium may pay up to an additional $135 million to Commave Seller upon achieving specified future AZSTARYS commercial and manufacturing milestones.
The amendment adds audited and unaudited consolidated financial statements of Corium Therapeutics Holdings, LLC and unaudited pro forma condensed combined financial statements of Collegium. Corium’s consolidated statements include both AZSTARYS and ADLARITY, but ADLARITY was not acquired and is excluded from the pro forma information, which reflects AZSTARYS only. Corium’s auditors highlighted recurring losses, net capital deficiency, and substantial doubt about Corium’s ability to continue as a going concern before the acquisition.
COLLEGIUM PHARMACEUTICAL, INC director Gino Santini exercised stock options to acquire 8,700 shares of Common Stock at $16.49 per share. These options were fully vested and exercisable. After the transaction, Santini directly holds 112,483 shares of Common Stock, and the exercised option covering 8,700 shares is fully used.
Collegium Pharmaceutical director John Gordon Freund reported a small open-market sale of common stock. On May 18, 2026, he sold 20 shares of Collegium Pharmaceutical common stock at $34.05 per share in a direct transaction.
After this sale, he directly held 83,952 common shares. The filing also shows indirect interests in entities holding 8,625 shares through Skyline Venture Management V, LLC and 23,129 shares through John Freund Family Partnership IV, L.P., with beneficial ownership disclaimed except for his proportionate pecuniary interest.
Lurker Nancy reported acquisition or exercise transactions in this Form 4 filing.
Collegium Pharmaceutical director Nancy Lurker received a grant of 8,741 restricted stock units (RSUs), each representing one share of common stock. These RSUs vest on the earlier of May 14, 2027, or the company’s 2027 annual shareholder meeting, if she continues serving as a director.
After this equity award, Lurker’s direct holdings total 26,758 shares of common stock. The RSUs will be settled in shares on vesting or, if she so elects, upon the earlier of her board service ending, her death or disability, or a change in control of Collegium Pharmaceutical.